Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort

Rockstroh, 2004, HIV and hepatitis C virus co-infection, Lancet Infect Dis, 4, 437, 10.1016/S1473-3099(04)01059-X

Soriano, 2004, Care of patients with hepatitis C and HIV co-infection, AIDS, 18, 1, 10.1097/00002030-200401020-00001

Filippini, 2003, Hepatitis viruses and HIV infection in the Naples area, Infect Med, 11, 139

Patrick, 2001, Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection, Can Med Assoc J, 165, 889

Zhang, 2002, High prevalence of HIV-1 and hepatitis C virus coinfection among injection drug users in the southeastern region of Yunnan, China, J Acquir Immune Defic Syndr, 29, 191, 10.1097/00042560-200202010-00014

Sherman, 2002, Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group, Clin Infect Dis, 34, 831, 10.1086/339042

Soriano, 1999, Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users, Eur J Epidemiol, 15, 1, 10.1023/A:1007506617734

Martin-Carbonero, 2001, Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients, AIDS Res Hum Retroviruses, 17, 1467, 10.1089/08892220152644160

Bica, 2001, Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection, Clin Infect Dis, 32, 492, 10.1086/318501

Soriano, 2002, Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel, AIDS, 16, 813, 10.1097/00002030-200204120-00001

Braitstein, 2005, Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients, Can Med Assoc J, 173, 160, 10.1503/cmaj.045202

Cacoub, 2001, Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French departments of internal medicine/infectious diseases, in 1995 and 1997, Clin Infect Dis, 32, 1207, 10.1086/319747

Greub, 2000, Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study, Lancet, 356, 1800, 10.1016/S0140-6736(00)03232-3

Hogg, 2002, Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up, AIDS, 16, 1051, 10.1097/00002030-200205030-00012

Low-Beer, 2000, Adherence to triple therapy and viral load response, J Acquir Immune Defic Syndr, 23, 360, 10.1097/00126334-200004010-00016

Wood, 2003, Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/l, Ann Intern Med, 139, 810, 10.7326/0003-4819-139-10-200311180-00008

Delgado, 2003, Highly active antiretroviral therapy: physician experience and enhanced adherence to prescription refill, Antivir Ther, 8, 471, 10.1177/135965350300800501

O'Connell, 2003, Age, adherence and injection drug use predict virological suppression among men and women enrolled in a population-based antiretroviral drug treatment programme, Antivir Ther, 8, 569, 10.1177/135965350300800601

Heath, 2002, Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy, J Acquir Immune Defic Syndr, 31, 211, 10.1097/00126334-200210010-00012

Palepu, 2004, Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment, Addiction, 99, 361, 10.1111/j.1360-0443.2003.00670.x

Wood, 2004, Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users, Antivir Ther, 9, 229, 10.1177/135965350400900218

Wood, 2003, Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users, Can Med Assoc J, 169, 656

Ripamonti, 2004, Hepatitis C infection increases the risk of the modification of first highly active antiretroviral therapy in HIV-infected patients, AIDS, 18, 334, 10.1097/00002030-200401230-00028

Melvin, 2000, The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy, AIDS, 14, 463, 10.1097/00002030-200003100-00023

d'Arminio Monforte, 2000, Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients, AIDS, 14, 499, 10.1097/00002030-200003310-00005

Braitstein, 2004, Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C, AIDS, 18, 2221, 10.1097/00002030-200411190-00002

Carpenter, 1996, Antiretroviral therapy for HIV infection in 1996, JAMA, 276, 146, 10.1001/jama.1996.03540020068031

Carpenter, 1997, Antiretroviral therapy for HIV infection in 1997, JAMA, 277, 1962, 10.1001/jama.1997.03540480062040

Carpenter, 2000, Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society-USA Panel, JAMA, 283, 381, 10.1001/jama.283.3.381

Yeni, 2002, Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel, JAMA, 288, 222, 10.1001/jama.288.2.222

Wood, 2003, Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?, AIDS, 17, 711, 10.1097/00002030-200303280-00009

Aceti, 2002, Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection, J Acquir Immune Defic Syndr, 29, 41, 10.1097/00042560-200201010-00005

Pradat, 2002, Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European Collaborative Study, Hepatology, 36, 973